載入...
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms. Th...
Na minha lista:
| 發表在: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5583255/ https://ncbi.nlm.nih.gov/pubmed/28871105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-00450-6 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|